Wells Fargo & Company Gilead Sciences, Inc. Put Options Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 10, 2024	SELL	$71.58 - $87.29 $71,580 - $87,290	-1,000 Reduced 20.83%	3,800 $278,000
Q2 2023 Aug 15, 2023	BUY	$76.01 - $86.7 $364,848 - $416,160	4,800 New	4,800 $369,000
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $150,592 - $188,708	-2,600 Reduced 46.43%	3,000 $178,000
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $126,000 - $143,766	2,100 Added 60.0%	5,600 $362,000
Q3 2020 Nov 05, 2020	BUY	$62.1 - $78.08 $124,200 - $156,160	2,000 Added 133.33%	3,500 $4,000
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $6.94 Million - $8.06 Million	-95,900 Reduced 98.46%	1,500 $1,000
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $6.1 Million - $7.81 Million	97,400 New	97,400 $316,000

1,926

993M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.